Ground-breaking research from UCL could mean new treatments for patients with cancers that have not responded to standard therapies.
The new therapies have evolved from research conducted by Dr Martin Pule and his team at the UCL Cancer Institute and NIHR University College London Hospitals Biomedical Research Centre.
The research was commercialised into a spinout company called Autolus in 2014. The spinout process was supported by UCL Business Ltd (UCLB), UCL's commercialisation company.
The company raised £30 million in investment from venture capital firm Syncona Partners. At the time this was one of the largest ever 'Series A' financing round for a European biotechnology company.
That was followed by 'Series B' funding of £40 million and 'Series C' funding of £59 million, before an IPO in 2018.
Find out how UCL spinouts solve complex global challenges and stimulate economic growth: https://ucl.ac.uk/enterprise
Find out more about UCLB: https://www.uclb.com
